Status:
UNKNOWN
Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer
Lead Sponsor:
Harbin Medical University
Conditions:
Stage IV Gastric Cancer With Metastasis
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional study，aim to observe the safety and efficiency of different treatment regimen for peritoneal metastasis of Stage IV gastric cancer in the real world
Eligibility Criteria
Inclusion
- 18 ≤ age
- Patients with histologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma, stage IV with peritoneal metastasis
- Didn't received any prior systemic chemotherapy
- Signed informed consent
Exclusion
- History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product
- Pregnancy or lactation women,
- Inadequate hematopoietic function： WBC≦3,500/mm3; ANC≦1,500/mm3; Platelet≦80,000/mm3
- Inadequate organ function which is defined as below:
- Total bilirubin \>2 pper limit of normal range (ULN); ALT / AST \> 2.5 upper limit of normal range (ULN); serum creatinine \> 1.5 mg/dL, and Ccr \> 60 ml/min (estimated by Cockcroft-Gault formulation);
- Symptomatic peripheral neuropathy
- Receiving a concomitant treatment with other fluoropyrimidines
- Fluoropyrimidines (DPD) congenital absence
- Other Situations which physicians suggesting are inadaptable for enrollment
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03237507
Start Date
July 1 2017
End Date
June 1 2020
Last Update
August 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081